Publication: 3663

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 42 (4) 399-409
Year:
2024
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-internal-user
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
13
Parents:
3123  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
Bristol Myers Squibb (BMS), Genentech, Pfizer, and Sanofi  
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA233253, UG1CA233327, UG1CA233373, UG1CA180830 and U10CA180888 (SWOG), R01CA143237  
Corr. Author:
 
Authors:
                   
Networks:
CA011, CA824, LAPS-MN026, LAPS-NC007, OR013   
Study
Alliance-A151813
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-80405
Phases:
N/A, 3
Keywords:
Humans, Bevacizumab, Cetuximab, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Microsatellite Instability, Standard of Care, Mutation, Antineoplastic Combined Chemotherapy Protocols